Cyxone AB (publ) (CYXO.ST)
Cyxone AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Malmö, SE. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $6.8M. Its beta of 0.42 implies it has historically moved less than the broad market.
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Cyxone AB (publ) is most often compared with the following Healthcare names: